EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Implications for medication safety and adherence in dermato‐oncology: The AMBORA care program for oral antitumor therapeutics

Lisa Cuba iD, Frank Dörje iD, Rafaela Kramer iD, Pauline Dürr iD, Michael Erdmann iD, Martin F Fromm iD, Carola Berking iD, Katja Gessner iD

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025

DOI: 10.1111/ddg.15809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Lisa Cuba und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Medication Adherence, Medication Errors, Skin Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Dermatological oral antitumor therapeutics (OAT) are often interaction‐prone and used in complex regimens. The pharmacological/pharmaceutical care program of the randomized AMBORA trial significantly improved medication safety with various OAT; however, dermato‐oncological patients were not included. It was subsequently implemented into clinical routine, including dermato‐oncology. We aimed to analyze medication errors and adherence in patients treated with any dermatological OAT. Patients and Methods Medication errors were characterized, for example, according to their cause (PCNE V9.1). Adherence was assessed using the Medication Event Monitoring System (MEMS ® Button) and the MARS‐D questionnaire. Primary outcomes were the percentage of resolved OAT‐involving errors and Dosing Adherence (DA) ; proportion of days with correct OAT intake) over 12 weeks.

Results

In 92 patients (81.5% melanoma), we detected 1.6 medication errors per patient and 61.6% involved the OAT. Thereof, 89.2% were resolved. Of 52 patients participating in the additional adherence monitoring, 48 were evaluable and reached a median DA of 95.0% and MARS‐D score of 25/25. DA was higher in once‐ vs. twice‐daily regimens (p = 0.0127).

Conclusions

The interprofessional AMBORA care program in dermato‐oncology was associated with the resolution of a large proportion of medication errors and high adherence. Evidence‐based medication management and patient counseling by clinical pharmacologists/pharmacists optimizes medication safety in dermato‐oncological practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMedication AdherenceMedication ErrorsSkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, OralGermanyRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Basal cell carcinomaT‐cell lymphomamelanomapharmacologyprotein kinase

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Pharmacy Department, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Comprehensive Cancer Center (CCC) Erlangen-EMN, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Bavarian Center for Cancer Research (BZKF), Erlangen, Germany.
  • Pharmacy Department, Clinic Floridsdorf, Vienna Healthcare Group, Vienna, Austria (present address).
  • FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Lisa Cuba, Frank Dörje, Rafaela Kramer, Pauline Dürr, Michael Erdmann, Martin F Fromm, Carola Berking, Katja Gessner

Zitieren

APA

Cuba, L., Dörje, F., Kramer, R., Dürr, P., Erdmann, M., Fromm, M. F., Berking, C., & Gessner, K. (2025). Implications for medication safety and adherence in dermato‐oncology: The AMBORA care program for oral antitumor therapeutics. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15809

Vancouver

Cuba L, Dörje F, Kramer R, Dürr P, Erdmann M, Fromm MF, et al. Implications for medication safety and adherence in dermato‐oncology: The AMBORA care program for oral antitumor therapeutics. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15809

BibTeX
@article{Cuba2025,
  author = {Cuba, Lisa and Dörje, Frank and Kramer, Rafaela and Dürr, Pauline and Erdmann, Michael and Fromm, Martin F and Berking, Carola and Gessner, Katja},
  title = {Implications for medication safety and adherence in dermato‐oncology: The AMBORA care program for oral antitumor therapeutics},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2025},
  doi = {10.1111/ddg.15809}
}
Kostenlos starten →